InnoCare Secures China Breakthrough Therapy Status for Marginal Zone Lymphoma Therapy
BEIJING, Aug. 4, 2026 InnoCare Pharma announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation...
Breakthrough Therapy Designation
Advertisement
Lundbeck Completes Enrollment in Phase III DEEp OCEAN Trial
VALBY, Denmark, July 20, 2026 H. Lundbeck A/S has reached a major clinical development milestone with the last patient...
Marengo Reports Phase II Breast Cancer Trial Success
CAMBRIDGE, Mass., April 17, 2026 Marengo Therapeutics has unveiled encouraging late-breaking Phase IIa clinical results for its investigational immunotherapy...
Persephoni Backs SelSym to Advance Trauma Bleeding Care
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 Persephoni BioSciences has announced a strategic investment in SelSym Biotech, bringing the...
Genentech Wins FDA Priority Review for Gazyva in pMN
SOUTH SAN FRANCISCO, Calif., July 14, 2026 Genentech, a member of the Roche Group, has received U.S. Food and...
Advertisements
Roche’s Gazyva Receives FDA Priority Review
BASEL, Switzerland, July 15, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review...
Dizal Licenses Zegfrovy to AstraZeneca in $1.5B Deal
SHANGHAI, China, July 14, 2026 Dizal has entered into a landmark global exclusive license agreement with AstraZeneca for Zegfrovy...
Avance Clinical Unveils Asia Growth Strategy at BIO Asia–Taiwan
TAIPEI, Taiwan | July 10, 2026 Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO), has announced its participation...
Leads Biolabs Secures Priority Review for Opamtistomig
NANJING, China | July 10, 2026 Nanjing Leads Biolabs Co., Ltd. has announced that the Center for Drug Evaluation...
InxMed Publishes Landmark Ifebemtinib NSCLC Trial Results
NANJING, China, July 9, 2026 InxMed Co., Ltd., a clinical-stage biotechnology company focused on overcoming cancer treatment resistance, has...
Advertisement
